The UK-based early phase drug development services provider currently employs more than 350 staff. The company’s Translational Pharmaceutics® platform integrates formulation development, real-time drug product manufacturing, and clinical testing.
SeaView is a clinical pharmacology business with 160 employees across two clinical pharmacology units in Miami and Jacksonville, Florida. The company has a combined bed capacity of 320 and supports various clinical research studies, including first-in-human investigations.
Mark Egerton, Quotient Clinical CEO, told us the US is a key strategic market for the company, with more than half its customers already based in the US.
“Establishing an operational footprint in the USA is an important strategic objective for Quotient to support continued growth and expansion,” Egerton said. “Quotient can now offer customers the option to undertake their early phase clinical research either in the UK or the USA.”
Additionally, the acquisition is “a key first component” towards the replication of Quotient’s Translational Pharmaceutics® platform in the USA.
“There will be a further US acquisition announced next week, which will complement the SeaView acquisition and go even further towards enabling Quotient to establish a US footprint,” added Egerton.
Quotient and SeaView have complementary service portfolios and customer portfolios, which are expected to provide “many potential synergies” to benefit customers of both companies.
Simply, Egerton explained the objective is to present customers with a wider range of options and solutions “so they can choose to work with Quotient however they wish.”